Follow-up study of enzymuria and β2 microglobulinuria during cis-platinum treatment

A. S. Tirelli, N. Colombo, G. Cavanna, C. Mangioni, B. M. Assael

Research output: Contribution to journalArticlepeer-review


Twenty patients with epithelian ovarian cancer treated with DDP (cis-diammine-dichloroplatinum II) 50 mg/m2 were followed for 24 weeks in order to assess the nephrotoxicity of the drug. Ten patients received the total dose in one day with heavy osmotic hydration (Group A), and for the other 10 the dose was subdivided over 3 consecutive days (Group B). The renal tubular toxicity of DDP treatment was evaluated over a total of 120 courses. After the first DDP administration, there was a prompt, reversable and dose-dependent increase in the urinary excretion of β2 microglobulin with no difference between the two groups: Group A from 405 to 990 and Group B from 109 to 585 ng/mg creatinine. An increase always occurred during subsequent courses, but it was significantly lower in Group B after the sixth course, from 125 to 331 ng/mg creatinine. A similar pattern was found for the urinary excretion of N-acetyl-glucosaminidase (NAG), a lysosomal enzyme of tubular origin. The percentage fraction of urinary sodium excretion (FeNa%) increased after each dose of DDP; Group A from 0.82 to 2.30 and Group B from 0.68 to 2.53. This effect was reversible and it occurred to the same extent during the subsequent courses. There was no impairment of the glomerular filtration rate. Thus, enzymuria and β2 microglobulin excretion are a sensitive tool to reveal minor tubular damage. Their use to predict serious renal dysfunction in longitudinal studies, however, seems questionable.

Original languageEnglish
Pages (from-to)313-318
Number of pages6
JournalEuropean Journal of Clinical Pharmacology
Issue number3
Publication statusPublished - May 1985


  • Cis-platinum
  • longitudinal study
  • N-acetyl-glucosamidase
  • nephrotoxicity
  • plasma and urinary beta microglobulin
  • side-effects
  • urinary sodium excretion

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)


Dive into the research topics of 'Follow-up study of enzymuria and β2 microglobulinuria during cis-platinum treatment'. Together they form a unique fingerprint.

Cite this